Clinical experience with OM-85 BV in upper and lower respiratory tract infections.

Abstract

The preventive effect of OM-85 BV on recurrent ENT and respiratory tract infections has been documented in a series of clinical trials. This article reviews the more significant controlled clinical trials investigating the efficacy and safety of OM-85 BV in airway infections. The literature reviewed covers all age groups. In summary, the administration of OM-85 BV was associated with a decrease in the number of acute exacerbations, with an increase in the number of patients remaining free from infections and with a decrease in antibiotic consumption. These results indicate the efficacy of oral immunostimulation with the bacterial extract OM-85 BV in all age groups and demonstrate its protective effect against recurrent airway infections.

• Authors: J P Derenne, B Delclaux
• Journal: Respiration; international review of thoracic diseases (Respiration) Vol. 59 Suppl 3 Pg. 28-31 ( 1992) ISSN: 0025-7931 [Print] Switzerland
• PMID: 1439237 (Publication Type: Journal Article, Review)

Chemical References

• Adjuvants, Immunologic
• Broncho-Vaxom
• Cell Extracts

Topics

• Adjuvants, Immunologic (therapeutic use)
• Bacteria
• Bronchitis (therapy)
• Cell Extracts
• Humans
• Randomized Controlled Trials as Topic
• Respiratory Tract Infections (therapy)
• Sinusitis (therapy)